On January 20, 2021 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") reported that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to 21st (Press release, Actinium Pharmaceuticals, JAN 20, 2021, View Source [SID1234574124]). During the event, Sandesh Seth, Actinium’s Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer will participate in a fireside chat discussion moderated by B. Riley analyst Justin Walsh.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fireside Chat Details

Event:

B. Riley Oncology Investor Conference

Participants:

Sandesh Seth, Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer

Date:

Thursday, January 21st

Time:

3:30 p.m. ET

In addition, members of the executive team will be available for one-on-one meetings with conference attendees. Those interested in scheduling a meeting may do so by contacting their B. Riley representative or the Company at [email protected].